Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies

Todd A. Smitherman(University of Mississippi), Eric Pearlman(University of California, San Francisco), Gretchen E. Tietjen(University of Vermont), Kory Schuh(Eli Lilly (United States)), Deborah N. D’Souza(Syneos Health (United States)), Vladimir Skljarevski(Eli Lilly (United States)), Sarah Lipsius(Syneos Health (United States))
Headache The Journal of Head and Face Pain
October 16, 2020
Cited by 35


Related Papers